This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.

 

This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?

Andreas
Liebl
Center for Diabetes and Metabolism at the Fachklinik, Bad Heilbrunn, Germany

Dr. Liebl is the Medical Director of the Center for Diabetes and Metabolism at the Fachklinik in Bad Heilbrunn, Germany. His research interests include insulin therapy, pharmacoeconomics, insulin pump therapy, intraperitoneal insulin therapy, continuous glucose monitoring and other diabetes technology. He is an advisor for the German Health Authorities and Payers Organisations.

 

Dr. Liebl has been a board member of ‘Diabetes Technology – Insulin Pumps and Glucose Sensors’ AGDT, which is a working group of the German Diabetes Association (DDG). He is also Past-Chairman and current board member of the Diabetes Expert Commission FKDB within the DDG, and an advisor for the German Health Authorities and Payers Organisations.

 

Dr. Liebl has authored or co-authored more than 100 national and international publications and has delivered numerous presentations at scientific meetings all over the world.

properties.alt

Ronald Goldenberg

LMC Diabetes & Endocrinology, Vaughan, Ontario, Canada


Dr Goldenberg is a consultant endocrinologist affiliated with LMC Diabetes & Endocrinology in Vaughan, Ontario. He completed his residency in Internal Medicine in 1987 and his fellowship in Endocrinology & Metabolism in 1989, both at the University of Toronto. His major areas of interest include clinical care of diabetes, obesity, dyslipidaemia and thyroid disorders.

 

Dr Goldenberg has been an investigator in a wide array of clinical trials in the areas of diabetes, hypertension, obesity and dyslipidaemia. He has been actively involved in Continuing Medical Education for the last 3 decades, with a strong focus on translating evidence-based medicine into practical patient care.

 

Dr Goldenberg was a councilor on the Diabetes Canada Clinical & Scientific Section Executive Committee from 2010 to 2016. He was also a member of the Steering Committee and an author for the 2013 CDA Clinical Practice Guidelines, lead author of the CDA March 2016 Interim Update and co-author of the November 2016 Interim Update on the Pharmacologic Management of Type 2 Diabetes. He has served on the Executive Committee and was an author for the 2018 Diabetes Canada Clinical Practice Guidelines.

 

Dr Goldenberg was affiliated with North York Branson/North York General Hospital from 1989 to 2020, where he served as Medical Director of the Diabetes Education Centre. He is Past-Chair of the Ontario Medical Association Section on Endocrinology & Metabolism and a previous President of the Toronto Diabetes Association.


Read full bio